C D Marsden1. Show Affiliations » 1. University Department of Clinical Neurology, National Hospital for Nervous Diseases, London, UK.
Abstract
Entities: Disease
Mesh: See more » 1-Methyl-4-phenylpyridinium/adverse effectsAdrenal Glands/transplantationAdultAntiparkinson Agents/adverse effectsAntiparkinson Agents/therapeutic useBrain ChemistryChildChild, PreschoolCytoplasmic Granules/pathologyDyskinesia, Drug-Induced/etiologyEnvironmental Pollutants/adverse effectsFetusHumansLevodopa/adverse effectsLevodopa/therapeutic useMiddle AgedPalliative CareParkinson Disease/diagnosisParkinson Disease/drug therapyParkinson Disease/epidemiologyParkinson Disease/etiologyPrevalenceResearchSelegiline/therapeutic useSubstantia Nigra/drug effectsSubstantia Nigra/pathologySubstantia Nigra/transplantationTime Factors
Substances: See more » Antiparkinson AgentsEnvironmental PollutantsSelegilineLevodopa1-Methyl-4-phenylpyridinium
Year: 1990 PMID: 1691427 DOI: 10.1016/0140-6736(90)91006-v
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321